Aktis Oncology is a clinical-stage company at the forefront of oncology innovation. With the compelling slogan, "Expanding the breakthrough potential of targeted radiopharmaceuticals to large cancer patient populations," the company underscores its commitment to addressing significant unmet needs in cancer treatment. Founded in 2020, Aktis Oncology, recently listed on Nasdaq as AKTS, focuses on leveraging its proprietary miniprotein radioconjugate platform.
The platform promises selective tumor targeting, minimizing radiation to normal tissues. This innovative approach is exemplified by their lead pipeline program targeting Nectin-4, which holds multi-indication potential. Significantly, Aktis Oncology has secured a strategic partnership with Eli Lilly and Company to explore targets beyond their pipeline.
The company's growth trajectory is supported by a substantial $365.40M IPO investment, dated 01 March 2026, with Avidity Partners playing a pivotal role as a key investor.
OncoNano Medicine, Inc.